Oh, really. I'd like to see that policy. Do they also have insurance for the loss in market share due to docs/patients saying "maybe we should take a safer option"? The company's response that they will consider further studies on the Durata after the FDA has ruled that there will be studies should really infuriate the regulator. The Company arrogance on the Riata issue from day 1 has been amazing. They laid off the issue on competitors passing rumors, on independent doctors "faulty" analysis and God knows what else.